Baha Alkuzweny

Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

Myron S. Czuczman, Robin Weaver, Baha Alkuzweny et al. · Journal of Clinical Oncology · 2004 · 364 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Myron S. Czuczman, Aron D. Thall, Thomas E. Witzig et al. · Journal of Clinical Oncology · 2005 · 148 citations · Full text

Pharmacy, Hematology, Pharmacokinetics +17

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

M. S. Czuczman, A.J. Grillo-López, Peter McLaughlin et al. · Annals of Oncology · 2001 · 67 citations · Full text

Medicine, Hematology, Oncology +13

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

M. S. Czuczman, A.J. Grillo-López, Baha Alkuzweny et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2006 · 26 citations

Medicine, Immunology, Oncology +16

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.

Rachel M. Layman, Katarzyna J. Jerzak, John Hilton et al. · Journal of Clinical Oncology · 2023 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +17